Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)

被引:5
作者
Murakami, Megumi [1 ]
Sajid, Andaleeb [1 ]
Lusvarghi, Sabrina [1 ]
Durell, Stewart R. [1 ]
Abel, Biebele [1 ]
Vahedi, Shahrooz [1 ]
Golin, John [2 ]
Ambudkar, Suresh V. [3 ]
机构
[1] NCI, NIH, Ctr Canc Res, Lab Cell Biol, Bethesda, MD 20892 USA
[2] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
[3] NCI, Cell Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 2120, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 日本学术振兴会;
关键词
ABC transporter; Multidrug resistance; P-glycoprotein; Second -site suppressors; Molecular dynamics simulations; MULTIDRUG-RESISTANCE; ATP HYDROLYSIS; CATALYTIC CYCLE; TRANSPORT; EXPRESSION; INHIBITION; SUBSTRATE; TRANSLOCATION; MODULATION; INTERFACE;
D O I
10.1016/j.drup.2023.101009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human P-glycoprotein (P-gp) or ABCB1 is overexpressed in many cancers and has been implicated in altering the bioavailability of chemotherapeutic drugs due to their efflux, resulting in the development of chemoresistance. To elucidate the mechanistic aspects and structure-function relationships of P-gp, we previously utilized a tyrosine (Y)-enriched P-gp mutant (15Y) and demonstrated that at least 15 conserved residues in the drug -binding pocket of P-gp are responsible for optimal substrate interaction and transport. To further understand the role of these 15 residues, two new mutants were generated, namely 6Y with the substitution of six residues (F72, F303, I306, F314, F336 and L339) with Y in transmembrane domain (TMD) 1 and 9Y with nine sub-stitutions (F732, F759, F770, F938, F942, M949, L975, F983 and F994) in TMD2. Although both the mutants were expressed at normal levels at the cell surface, the 6Y mutant failed to transport all the tested substrates except Bodipy-verapamil, whereas the 9Y mutant effluxed all tested substrates in a manner very similar to that of the wild-type protein. Further mutational analysis revealed that two second-site mutations, one in intracellular helix (ICH) 4 (F916Y) and one in the Q loop of nucleotide-binding domain (NBD) 1 (F480Y) restored the transport function of 6Y. Additional biochemical data and comparative molecular dynamics simulations of the 6Y and 6Y+F916Y mutant indicate that the Q-loop of NBD1 of P-gp communicates with the substrate-binding sites in the transmembrane region through ICH4.This is the first evidence for the existence of second-site suppressors in human P-gp that allow recovery of the loss of transport function caused by primary mutations. Further study of such mutations could facilitate mapping of the communication pathway between the substrate-binding pocket and the NBDs of P-gp and possibly other ABC drug transporters.
引用
收藏
页数:13
相关论文
共 33 条
  • [21] Mutations in Intracellular Loops 1 and 3 Lead to Misfolding of Human P-glycoprotein (ABCB1) That Can Be Rescued by Cyclosporine A, Which Reduces Its Association with Chaperone Hsp70
    Kapoor, Khyati
    Bhatnagar, Jaya
    Chufan, Eduardo E.
    Ambudkar, Suresh V.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (45) : 32622 - 32636
  • [22] Promoter Haplotypes of the ABCB1 Gene Encoding the P-Glycoprotein Differentially Affect Its Promoter Activity by Altering Transcription Factor Binding
    Speidel, Jordan T.
    Xu, Meixiang
    Abdel-Rahman, Sherif Z.
    DNA AND CELL BIOLOGY, 2018, 37 (12) : 973 - 981
  • [23] Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1)
    Hitzl, M
    Schaeffeler, E
    Hocher, B
    Slowinski, T
    Halle, H
    Eichelbaum, M
    Kaufmann, P
    Fritz, P
    Fromm, MF
    Schwab, M
    PHARMACOGENETICS, 2004, 14 (05): : 309 - 318
  • [24] Computational binding affinity and molecular dynamic characterization of annonaceous acetogenins at nucleotide binding domain (NBD) of multi-drug resistance ATP-binding cassette sub-family B member 1 (ABCB1)
    Manoharan, Jeevitha Priya
    Nirmala Karunakaran, Kavinkumar
    Vidyalakshmi, Subramanian
    Dhananjayan, Karthik
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (03) : 821 - 832
  • [25] Catalytic Transitions in the Human MDR1 P-Glycoprotein Drug Binding Sites
    Wise, John G.
    BIOCHEMISTRY, 2012, 51 (25) : 5125 - 5141
  • [26] ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein
    Dickens, David
    Owen, Andrew
    Alfirevic, Ana
    Pirmohamed, Munir
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (06) : 314 - 323
  • [27] IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies
    Saaby, Lasse
    Helms, Hans Christian Cederberg
    Brodin, Birger
    MOLECULAR PHARMACEUTICS, 2016, 13 (02) : 640 - 652
  • [28] A Site-Directed Mutagenesis Study of Drug-Binding Selectivity in Genetic Variants of Human α1-Acid Glycoprotein
    Nishi, Koji
    Ueno, Megumi
    Murakami, Yuka
    Fukunaga, Naoko
    Akuta, Teruo
    Kadowaki, Daisuke
    Watanabe, Hiroshi
    Suenaga, Ayaka
    Maruyama, Toru
    Otagiri, Masaki
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (11) : 4316 - 4326
  • [29] Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver
    Owen, A
    Goldring, C
    Morgan, P
    Chadwick, D
    Park, BK
    Pirmohamed, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) : 365 - 370
  • [30] Chalcogenopyrylium Compounds as Modulators of the ATP-Binding Cassette Transporters P-Glycoprotein (P-gp/ABCB1) and Multidrug Resistance Protein 1 (MRP1/ABCC1)
    Ebert, Sean P.
    Wetzel, Bryan
    Myette, Robert L.
    Conseil, Gwenaelle
    Cole, Susan P. C.
    Sawada, Geri A.
    Loo, Tip W.
    Bartlett, M. Claire
    Clarke, David M.
    Detty, Michael R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (10) : 4683 - 4699